These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 812541)

  • 21. [Eutergine and retinal arteriosclerosis].
    Ourgaud AG; Metge P; Cazenave P
    Bull Soc Ophtalmol Fr; 1975; 75(5-6):591-607. PubMed ID: 813835
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine.
    Loew DM; Jaton AL; Vigouret JM
    Postgrad Med J; 1976; 52suppl 1():40-46. PubMed ID: 822407
    [No Abstract]   [Full Text] [Related]  

  • 23. [Plasma levels and biliary and urinary elimination of raubasine, dehydroergocristine and dihydroergotamine after venous administration in anesthetized dogs].
    Marzo A; Ghirardi P; Parenti MA; Merlo L; Marchetti G
    Boll Soc Ital Biol Sper; 1975 Jun; 51(11):684-6. PubMed ID: 816365
    [No Abstract]   [Full Text] [Related]  

  • 24. [Study on the psychodynamic effect of dihydroergotoxin].
    Heiss R; Seus R; Fahrenberg J
    Arzneimittelforschung; 1971 Jun; 21(6):797-800. PubMed ID: 4998089
    [No Abstract]   [Full Text] [Related]  

  • 25. Separation of dihydroergotoxine (hydergine) into dihydroergocornine, dihydroergocryptine and dihydroergocristine by counter-current distribution.
    Galeffi C; Delle Monache EM
    J Chromatogr; 1974 Jan; 88(2):413-5. PubMed ID: 4205319
    [No Abstract]   [Full Text] [Related]  

  • 26. [Acute changes in intracerebral vascular resistance after application of dihydrogenated ergot alkaloids (author's transl)].
    Vaupel P; Hutten H
    Arzneimittelforschung; 1980; 30(4):598-602. PubMed ID: 6772196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical pharmacology of adrenergic agonists and antagonists. I. Alpha-adrenergic agonists and antagonists].
    Hugues FC; Baillet J; Sardal J; Marche J
    Coeur Med Interne; 1972; 11(4):749-55. PubMed ID: 4405691
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment by sandoven-f in patients with venous affections (author's transl)].
    Viviani E
    Schweiz Rundsch Med Prax; 1975 Oct; 64(41):1320-3. PubMed ID: 815900
    [No Abstract]   [Full Text] [Related]  

  • 29. [Study on the function of the sinus node and supra- and sub-Hisian A-V conduction in subjects with excitocondution changes after a dihydroergocristine test].
    Molinis G; Disertori M; Inama G; Furlanello F
    Minerva Cardioangiol; 1976 Jan; 24(1):1-7. PubMed ID: 815847
    [No Abstract]   [Full Text] [Related]  

  • 30. Helping to make the final years meaningful for the elderly residents of nursing homes.
    Einspruch BC
    Dis Nerv Syst; 1976 Aug; 37(8):439-42. PubMed ID: 821734
    [No Abstract]   [Full Text] [Related]  

  • 31. Hydergine-thioridazine combination in the treatment of psychopathological states in old age.
    Predescu V; Giurezu T; Tudorache D; Nica S; Ionescu R; Nicolschi L; Nitrurad A; Popvici E; Curelaru S
    Act Nerv Super (Praha); 1974 Aug; 16(3):237-8. PubMed ID: 4214302
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cerebral ictus and dihydroergotoxin methanesulfonate: a year of therapeutic trial].
    Copti MC; Bissoon-Doyal D; Lefebvre M
    Union Med Can; 1973 Aug; 103(8):1694-9. PubMed ID: 4209995
    [No Abstract]   [Full Text] [Related]  

  • 33. Ergoloid mesylates and ECT.
    Sachs GS; Gelenberg AJ; Bellinghausen B; Wojcik J; Falk WE; Farhadi AM; Jenike M
    J Clin Psychiatry; 1989 Mar; 50(3):87-90. PubMed ID: 2647711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of slow-release co-dergocrine mesylate (dihydroergotoxine) formulations.
    Woodcock BG; Habedank WD; Loh W; Herrmann W; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1987 Dec; 25(12):660-3. PubMed ID: 3436686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dihydroergotoxine (Hydergine) and phenothiazines on conditioned avoidance reflexes and body temperature of the rat.
    Bálint G; Anokbonggo WW
    Acta Physiol Acad Sci Hung; 1968; 33(1):95-8. PubMed ID: 4968607
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinico-rheographic study of the cerebrovascular effect of alpha-adrenergic blockers in vascular diseases of the brain].
    Shtok VN; Varlamova IV; Fedorova NV; Timurbaator
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(9):1333-8. PubMed ID: 4072531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A multicenter trial of treatment with slow-release dihydroergotoxine in chronic senile cerebral insufficiency].
    Franchi F; Di Ruvo R; Guggino G; Mazzanti A; Genga A; Cucinotta D
    G Clin Med; 1982 Jul; 63(7):465-81. PubMed ID: 6757035
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination therapy with lecithin and ergoloid mesylates for Alzheimer's disease.
    Jenike MA; Albert MS; Heller H; LoCastro S; Gunther J
    J Clin Psychiatry; 1986 May; 47(5):249-51. PubMed ID: 3700343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison between in vitro dissolution and in vivo absorption of a new form of delayed-action theophylline].
    Brazier JL; Comet F; Bannier A; Gillet A; Georges D
    Ann Pharm Fr; 1985; 43(1):55-60. PubMed ID: 4062182
    [No Abstract]   [Full Text] [Related]  

  • 40. Bioavailability of ergoloid mesylates liquid capsule.
    Schran HF
    Clin Ther; 1985; 8(1):71-5. PubMed ID: 3833371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.